Net income retreated to 22 million euros ($29.3 million) from 68.4 million euros in 2010, the company, based in Bad Vilbel, Germany, said in a statement today. Adjusted net income climbed 10 percent to 146.6 million euros, it said. Adjusted earnings per share reached 2.49 euros, more than the 2.35-euro average of 18 analysts’ estimates compiled by Bloomberg.
“Despite difficult framework conditions in individual national markets, particularly in Serbia and Germany, all operational key earnings figures are expected to have increased” in 2011, Stada said.
The German drug maker acquired Serbia’s Hemofarm Koncern AD for 480 million euros in 2006, as part of a push to shift manufacturing capacity as well as sales into eastern Europe. In November last year, the company announced a 96.9 million-euro writedown before taxes during the third quarter for unpaid bills from its Serbian business.
The company said today the “challenging framework conditions” will probably continue in some markets this year. Stada said it expects a “clear increase” in full-year sales, helped by acquisitions, including the purchase of a branded product portfolio from Gruenenthal GmbH over the past months.
The shares gained as much as 1.3 percent after the announcement, erasing an earlier decline in Frankfurt trading. The stock was up 0.2 percent to 23.02 euros at 1:43 p.m.
Stada proposed an unchanged dividend of 37 cents a share.
To contact the reporter on this story: Albertina Torsoli in Paris at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org